Neoadjuvant Chemotherapy for Resectable Cancer of the Pancreatic Head
Neodajuvant chemotherapy with gemcitabine / cisplatin is applied to patients with resectable
cancer of pancreatic head. Two cycles of chemotherapy are given on day 1 and 15 each. After
restaging excludes disease progression, a standard Whipple procedure is performed.
Staging and restaging procedures include abdominal CT, diagnostic laparoscopy, PET/CT, tumor
markers (CEA, CA 19-9) and assessment of the quality of life by the QLQ-30.
- Trial with medicinal product
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Resectability rate > 70% after restaging
01 Studienregister MasterAdmins